Famciclovir
Based on 1 publication(s) in Google Scholar
Famciclovir (BRL 42810) is an orally active nucleoside analogue. Famciclovir is an antiviral agent with potent activities against HBV, HSV and VZV. Famciclovir can be used for the research of herpesvirus infection.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 104227-87-4
- Formula: C14H19N5O4
- Molecular Weight:321.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Nucleotide Compound Library
HY-L044
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Famciclovir
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | CC50 |
>500 μM
Compound: famciclovir
|
Compound was tested for cytotoxicity in Vero cells (concentration required to reduce the OD value by 50% of the control)
Compound was tested for cytotoxicity in Vero cells (concentration required to reduce the OD value by 50% of the control)
|
[PMID: 9719596] |
| Vero | EC50 |
>100 μM
Compound: Famciclovir
|
Compound was tested for its antiviral activity against HSV-1(KOS strain) in vero cells
Compound was tested for its antiviral activity against HSV-1(KOS strain) in vero cells
|
10.1016/0960-894X(96)00329-0 |
| WI-38 | CC50 |
>0.78 μM
Compound: Famciclovir
|
Cytotoxicity against human WI38 cells by neutral red assay
Cytotoxicity against human WI38 cells by neutral red assay
|
[PMID: 18285481] |
| WI-38 | EC50 |
>0.78 μM
Compound: Famciclovir
|
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
|
[PMID: 18285481] |
Famciclovir metabolizes into BRL 42359 by deacetylation and then oxidizes to penciclovir[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Four- to five-week-old Balb/c mice with HSV-1 infection[1]
-
Dosage:50, 100, 200 and 400 mg/kg
-
Administration:Oral gavage; 50-400 mg/kg per day divided into three doses given every 8 h; for total 10 doses
-
Result:Significantly reduced the incidence of hepatitis with a dose of 50 mg/kg per day, and could not isolated infectious virus from the doses of 50 and 100 mg/kg treatment group.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 104227-87-4
-
Appearance Solid
-
Molecular Weight 321.33
-
Formula C14H19N5O4
-
Color White to off-white
-
SMILES
NC1=NC=C2N=CN(CCC(COC(C)=O)COC(C)=O)C2=N1
-
Synonyms
BRL 42810
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
BMC Cancer
Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer. [Abstract]2024 Mar 25;24(1):371. PMID: 38528462
Solvent & Solubility
DMSO : ≥ 100 mg/mL (311.21 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (155.60 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 120 mg/mL (373.45 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wutzler P, Ulbricht A, Färber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology. 1997;40(1):15-21. [Content Brief]
[2]. administration are replication defective. Hepatology. 1998 Feb;27(2):628-33. [Content Brief]
[3]. Harrell AW, et al. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.1121 mL | 15.5603 mL | 31.1207 mL | 77.8016 mL |
| 5 mM | 0.6224 mL | 3.1121 mL | 6.2241 mL | 15.5603 mL | |
| 10 mM | 0.3112 mL | 1.5560 mL | 3.1121 mL | 7.7802 mL | |
| 15 mM | 0.2075 mL | 1.0374 mL | 2.0747 mL | 5.1868 mL | |
| 20 mM | 0.1556 mL | 0.7780 mL | 1.5560 mL | 3.8901 mL | |
| 25 mM | 0.1245 mL | 0.6224 mL | 1.2448 mL | 3.1121 mL | |
| 30 mM | 0.1037 mL | 0.5187 mL | 1.0374 mL | 2.5934 mL | |
| 40 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL | 1.9450 mL | |
| 50 mM | 0.0622 mL | 0.3112 mL | 0.6224 mL | 1.5560 mL | |
| 60 mM | 0.0519 mL | 0.2593 mL | 0.5187 mL | 1.2967 mL | |
| 80 mM | 0.0389 mL | 0.1945 mL | 0.3890 mL | 0.9725 mL | |
| 100 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.7780 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Famciclovir Related Classifications
HY-17426 Related Classifications
Powered by Bioz